Last updated: September 24, 2026
Tiopronin is an oral thiol drug used to reduce urinary cystine in patients with cystinuria who do not respond adequately to high-fluid intake, alkalinization, and dietary measures. The commercial opportunity is concentrated in formulation differentiation rather than new chemical entities. The strongest opportunities are lower-cost delayed-release tablets, pediatric liquid or multiparticulate products, improved adherence formats, and formulations that reduce handling, swallowing, and gastrointestinal barriers.
The key technical issue is chemical and physical control of a sulfur-containing active ingredient during manufacturing and storage. Excipient selection should prioritize low moisture, low peroxide burden, compatibility with thiol chemistry, robust content uniformity at relatively high drug load, and preservation of delayed-release performance where applicable.
What is tiopronin and which dosage forms are commercially relevant?
Tiopronin, also known as N-(2-mercaptopropionyl)glycine, is a small-molecule thiol with a molecular weight of approximately 163.19 g/mol. It is marketed in oral tablet products for cystinuria. FDA-approved products include immediate-release tiopronin tablets and the delayed-release product Thiola EC, available in 100 mg and 300 mg strengths.[1,2]
| Attribute |
Commercial relevance |
| Active ingredient |
Tiopronin |
| Therapeutic area |
Cystinuria |
| Administration |
Chronic oral treatment |
| Established strengths |
100 mg and 300 mg tablets |
| Primary product formats |
Immediate-release and delayed-release tablets |
| Patient population |
Rare-disease, chronic-use population, including pediatric patients |
| Key formulation challenge |
Thiol stability, high tablet burden, swallowing and adherence |
| Regulatory pathway |
505(b)(2) or abbreviated pathway may be relevant depending on formulation and reference product |
Patients may require multiple tablets daily because dosing is weight-based and treatment is chronic. That creates an opportunity for higher-strength units, multiparticulate products, pediatric dosage forms, and packaging that improves daily compliance.
What excipients are important in tiopronin formulations?
The best excipient system depends on whether the product is immediate-release, delayed-release, liquid, or multiparticulate. Excipients should be selected based on compatibility with tiopronin, dissolution performance, manufacturability, and the intended regulatory pathway.
Immediate-release tablet excipients
A conventional immediate-release tablet may use:
- Microcrystalline cellulose as a dry binder and compression aid
- Lactose or mannitol as a diluent, subject to compatibility and patient considerations
- Crospovidone or croscarmellose sodium as a disintegrant
- Colloidal silicon dioxide as a flow aid
- Magnesium stearate or another lubricant at a controlled concentration
- Low-moisture film-coating materials for identification and swallowability
Tiopronin is likely to require careful control of excipient moisture, residual peroxides, and metal impurities. Thiol compounds can be vulnerable to oxidation. Peroxide-containing excipients, oxidizing processing aids, and high-moisture conditions should be screened early.
The formulation should avoid excessive lubricant levels because hydrophobic lubrication can slow wetting and dissolution. A short blending time and controlled lubricant addition are preferable, particularly for high-dose tablets.
Delayed-release tablet excipients
Delayed-release tiopronin products require two formulation layers:
- A core that protects drug performance during compression and storage.
- An enteric coating that prevents release in the stomach and promotes release at a higher intestinal pH.
Potential enteric polymers include methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, and polyvinyl acetate phthalate. The commercial selection depends on target dissolution behavior, coating process, stability, and reference-product comparability.
The coating system may include:
- An enteric polymer
- A plasticizer such as triethyl citrate or polyethylene glycol
- Talc or another anti-tacking agent
- A protective subcoat where needed
- Titanium dioxide or approved colorants for product identification
The coating must withstand gastric exposure without premature release. It also must avoid excessive delay or incomplete release in the intestine. For a generic or 505(b)(2) product, dissolution matching across multiple pH conditions is likely to be more important than simply reproducing the qualitative excipient list.
What excipient risks are specific to tiopronin?
Tiopronin’s thiol group creates a formulation risk that is less prominent in many conventional oral drugs. The highest-priority risks are oxidation, metal-catalyzed degradation, moisture exposure, and interaction with packaging components.
Oxidation and peroxide burden
Polyethylene glycol, povidone, crospovidone, and some other excipients can contain variable peroxide levels. These materials should be sourced with controlled peroxide specifications and evaluated by supplier lot. A compatibility program should compare fresh and aged excipient lots under accelerated conditions.
The development program should monitor:
- Tiopronin assay
- Oxidation-related degradants
- Total impurities
- Dissolution
- Water content
- Tablet hardness and friability
- Disintegration
- Coating integrity for delayed-release products
Metal impurities
Trace metals can catalyze oxidation of sulfur-containing compounds. Excipient suppliers should provide elemental impurity controls consistent with ICH Q3D expectations. Chelating excipients may reduce some risks, but they can also change dissolution, taste, absorption, or regulatory complexity. They should not be added without demonstrated benefit.
Moisture and packaging
A low-moisture formulation may require:
- High-barrier blister packaging
- Desiccant-containing bottles
- Induction seals
- Low water-vapor transmission polymer bottles
- In-process humidity controls
- Moisture-specific release specifications
Packaging is part of the excipient and formulation strategy. A lower-cost tablet that requires expensive protective packaging may not produce a meaningful cost advantage.
What formulation patents protect tiopronin products?
Tiopronin’s main intellectual-property value is more likely to reside in specific drug products, delayed-release systems, manufacturing controls, and pediatric or alternative dosage forms than in broad composition-of-matter protection for the active ingredient.
Potentially relevant patent categories include:
| Patent category |
Commercial effect |
| Delayed-release tablet |
May restrict direct substitution with an immediate-release product |
| Enteric coating system |
Can support product differentiation and regulatory bridging |
| Multiparticulate dosage form |
May protect pediatric or swallowing-friendly delivery |
| Liquid or suspension formulation |
May support a 505(b)(2) product |
| Manufacturing process |
Can create barriers if impurity control depends on specialized processing |
| Packaging and stability |
May support a product-specific shelf-life advantage |
| Method of use |
May cover dosing or treatment populations, subject to enforceability and listing rules |
Orange Book status, patent numbers, expiration dates, and litigation positions must be assessed against the current FDA Orange Book, FDA approval records, USPTO records, and court dockets before making a launch or freedom-to-operate decision.[3-5] Formulation patents may be listed differently from method-of-use patents, and not every patent relevant to commercial risk is necessarily listed in the Orange Book.
When does tiopronin lose exclusivity and what is the generic-entry risk?
Tiopronin is an older active ingredient, so active-ingredient exclusivity is unlikely to be the primary barrier to competition. The more important issues are product-specific approval requirements, formulation similarity, manufacturing capability, and commercial scale.
Generic-entry risk differs by product type:
| Product type |
Generic or follow-on risk |
Main barrier |
| Immediate-release tablet |
High |
Bioequivalence and impurity control |
| Delayed-release tablet |
Moderate |
Multi-stage dissolution and coating performance |
| Pediatric liquid |
Moderate |
Stability, taste, preservative system, dosing accuracy |
| Sprinkle or multiparticulate product |
Moderate to low initially |
Food effect, dose uniformity, in-use stability |
| Novel combination or regimen |
Lower |
Clinical and regulatory evidence |
A Paragraph IV challenge could target listed formulation or method-of-use patents. The commercial significance depends on whether the challenged patent covers the reference product’s core dosage form, a narrow use, or a nonessential feature. A generic company may also pursue a Paragraph III certification, a section viii statement for carved-out uses, or a product with a different release profile.
The most important launch scenarios are:
- A direct generic immediate-release tablet enters at a lower price.
- A delayed-release generic follows after demonstrating comparable dissolution.
- A 505(b)(2) product enters with a pediatric or liquid formulation.
- A product launches with a different dosage form and competes on adherence rather than price.
- A branded product preserves share through patient support, specialty distribution, and improved administration.
What commercial opportunities exist for tiopronin excipient innovation?
Lower-cost delayed-release tablets
A robust delayed-release tablet with fewer manufacturing steps, lower coating weight, and reduced packaging cost could compete against an established branded product. The opportunity depends on achieving dissolution equivalence without increasing impurity formation or batch rejection rates.
A scalable approach would use a directly compressible core, a controlled low-moisture process, and a standard enteric coating platform. The highest-value development work would focus on coating uniformity, acid resistance, intestinal release, and stability under high humidity.
Pediatric liquid formulation
Cystinuria affects children, and tablet swallowing can limit adherence. A liquid formulation could support weight-based dosing and reduce tablet burden. The technical challenges include:
- Tiopronin solubility and chemical stability
- Thiol oxidation in an aqueous environment
- Taste masking
- Preservative compatibility
- Dose uniformity after storage
- In-use stability after opening
- Packaging compatibility
A dry powder for reconstitution may be more attractive than a ready-to-use liquid if oxidation and shelf-life constraints are substantial. Unit-dose sachets or bottles could reduce repeated exposure to oxygen and moisture.
Multiparticulate and sprinkle products
A coated multiparticulate formulation could be administered with soft food or a suitable beverage, subject to labeling and demonstrated stability. This approach may reduce swallowing difficulty while retaining delayed release.
The key regulatory tests would include:
- Particle-size distribution
- Drug-layer uniformity
- Coating thickness
- Acid-stage resistance
- Intestinal-stage release
- Dose recovery from the administration vehicle
- Stability after sprinkling or mixing
This product could support pediatric use without the full complexity of an aqueous liquid.
High-strength tablets and adherence packaging
A 300 mg unit may reduce pill burden compared with repeated 100 mg dosing. A commercial platform could include 100 mg and 300 mg tablets with calendar packaging, dose cards, or blister configurations aligned with weight-based treatment.
Packaging is unlikely to create a durable patent barrier by itself, but it can improve adherence and differentiate a product in a rare-disease market where patient support influences prescribing.
Excipient and component supply opportunities
Specialty suppliers can compete through:
- Low-peroxide excipients
- Low-moisture direct-compression grades
- Controlled elemental impurity profiles
- Enteric coating systems with reproducible dissolution
- High-barrier packaging
- Stability-indicating analytical methods
- Custom premixes for contract manufacturers
The strongest supplier opportunity is a qualified formulation platform rather than a commodity excipient. A supplier that can provide compatibility data, process guidance, and regulatory documentation may reduce development time for manufacturers.
How does tiopronin compare with other cystinuria treatments?
Tiopronin competes with hydration, urinary alkalinization, dietary management, and other thiol-based treatments. Its commercial positioning is strongest in patients who require pharmacologic reduction of cystine after conservative measures are inadequate.
| Treatment approach |
Formulation opportunity |
Commercial limitation |
| Hydration |
Liquid and adherence products |
Does not replace pharmacologic therapy |
| Urinary alkalinization |
Sachets, liquids, modified-release products |
Different mechanism and administration burden |
| Tiopronin |
Delayed-release, liquid, multiparticulate tablets |
Oxidation and high-dose formulation challenges |
| Other thiol agents |
Alternative oral dosage forms |
Different tolerability and regulatory profiles |
| Surgical stone management |
Devices and procedures |
Treats consequences rather than cystine formation |
Tiopronin is not a biologic. Biosimilar risk is therefore not applicable. The competitive threat comes from generic oral products, alternative thiol therapies, and improved adherence formats.
What FDA regulatory issues affect tiopronin formulation development?
FDA development strategy depends on the relationship between the proposed product and the reference product. A direct generic tablet may rely primarily on ANDA requirements. A new release profile, liquid, sprinkle product, or other clinically distinct dosage form may require a 505(b)(2) application and additional clinical or pharmacokinetic evidence.[3]
Critical regulatory issues include:
- Demonstrating bioequivalence for the relevant dosage form
- Matching delayed-release dissolution across pH stages
- Establishing impurity specifications
- Controlling oxidation-related degradants
- Demonstrating stability in the proposed container-closure system
- Justifying excipient differences
- Providing pediatric administration data where the product is designed for children
- Assessing food effects for modified-release or multiparticulate products
The FDA label should control claims regarding administration, tablet manipulation, food, storage, and dosage. A delayed-release product should not be positioned as interchangeable with an immediate-release product without the required regulatory basis.[1,2]
How strong is the tiopronin formulation opportunity?
The commercial opportunity is moderate to strong for differentiated delivery systems and moderate for a simple tablet generic. The strongest product concepts are those that solve a documented use problem rather than merely change excipients.
| Opportunity |
Technical attractiveness |
Commercial attractiveness |
| Low-cost immediate-release generic |
Moderate |
Moderate |
| Delayed-release generic |
High |
High |
| Pediatric dry powder for reconstitution |
High |
High |
| Ready-to-use liquid |
Moderate |
Moderate to high |
| Sprinkle multiparticulate |
High |
High |
| Novel excipient-only differentiation |
Low |
Low |
| High-barrier packaging platform |
Moderate |
Moderate |
Revenue exposure is concentrated in chronic treatment volume and price. A low-volume rare-disease product can still support attractive economics because patients may remain on therapy for years, but the addressable market is limited and payer scrutiny can increase after generic entry.
What patent litigation and settlement issues should companies monitor?
Companies should monitor:
- ANDA filings with Paragraph IV certifications
- Patent infringement complaints under the Hatch-Waxman framework
- Preliminary injunction motions
- Consent judgments and settlement agreements
- Authorized-generic arrangements
- Orange Book delistings or changes
- FDA approval dates for competing strengths and release profiles
- Product-specific manufacturing patents
- Licensing deals involving pediatric, liquid, or modified-release technology
A settlement may delay generic entry, permit an authorized generic, or limit the entrant to a particular dosage form or indication. The commercial effect cannot be determined from the existence of litigation alone. Claim scope, launch restrictions, exclusivity provisions, and the status of the reference product must be reviewed together.
Key Takeaways
- Tiopronin formulation value is concentrated in delivery technology, not the old active ingredient.
- Thiol oxidation, moisture, peroxide impurities, and trace metals should drive excipient screening.
- Delayed-release tablets are the most commercially defensible near-term opportunity.
- Pediatric liquids, dry powders, and multiparticulate sprinkle products address swallowing and adherence barriers.
- High-barrier packaging is part of the stability strategy and can materially affect product cost.
- Generic risk is higher for immediate-release tablets and more complex for delayed-release products.
- Patent and litigation analysis must distinguish Orange Book-listed patents from broader formulation, manufacturing, and method-of-use rights.
- Tiopronin has no biosimilar pathway because it is a small-molecule drug.
- The strongest product concept combines low oxidation risk, reproducible dissolution, lower tablet burden, and a regulatory pathway proportionate to the formulation change.
FAQs
Can tiopronin be formulated as an oral liquid?
Yes. An oral liquid is technically possible, but aqueous exposure increases the risk of oxidation, preservative incompatibility, taste problems, and short in-use stability. A dry powder for reconstitution may provide a more manageable stability profile.
Which excipients should be avoided in tiopronin tablets?
Excipients with high or variable peroxide content, uncontrolled moisture, or significant trace-metal contamination should be treated as high-risk until compatibility is demonstrated. Lubricants should also be controlled because excess hydrophobic material can impair dissolution.
Is an enteric-coated tiopronin product automatically substitutable with an immediate-release tablet?
No. Release profile, labeling, bioequivalence, and FDA approval status determine substitution. An enteric-coated product should not be treated as therapeutically interchangeable solely because it contains the same active ingredient.
Is tiopronin suitable for an orally disintegrating tablet?
An orally disintegrating tablet may reduce swallowing difficulty, but it may be a weak commercial fit if the product requires delayed release or if the thiol has unacceptable taste and oxidation behavior. Taste masking and release control would need to be solved together.
What is the most attractive excipient-supplier opportunity?
The strongest opportunity is a qualified low-peroxide, low-moisture excipient and coating platform supported by compatibility, dissolution, and stability data. Commodity supply alone is less defensible than a formulation package linked to regulatory development.
References
-
U.S. Food and Drug Administration. (2024). Thiola EC (tiopronin) delayed-release tablets: Prescribing information. Mission Pharmacal Company.
-
U.S. Food and Drug Administration. (2024). Tiopronin tablets: Prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides and other complex drug products. FDA.
-
International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. ICH.
-
International Council for Harmonisation. (2023). ICH Q1A(R2): Stability testing of new drug substances and products. ICH.
